{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 51 of 129', 'Subjects will be re-randomised to continuation treatment at Week 16. The treatment during', 'this period will depend on the regimen received in the initial treatment period and the', \"subject's clinical response at Week 16. Subjects randomised to tralokinumab who have a\", 'clinical response at Week 16 (i.e. IGA 0/1 or EASI75), will be re-randomised to the', 'continuation treatment period in a 1:1 ratio (tralokinumab Q2W:tralokinumab Q4W) stratified', 'by region and IGA response at Week 16 (IGA 0/1 or IGA>1). Subjects randomised to placebo', 'who have a clinical response at Week 16 will continue on placebo. Subjects in either the', 'tralokinumab or placebo group who have not achieved a clinical response at Week 16 will', 'receive tralokinumab Q2W in the continuation treatment period.', 'IWRS will be used to control randomisation, re-randomisation, and stratification factors,', 'along with IMP supply chain and expiry tracking, and for dispensing and return of NIMP', '(TCS).', '9.2.1 Blinding', 'This is a double-blinded trial in which tralokinumab and placebo are visually distinct from', 'each other. Neither the subject nor any of the investigator or LEO staff who are involved in', 'the treatment or clinical evaluation and monitoring of the subjects will be aware of the', 'treatment received.', 'The packaging and labelling of the IMPs will contain no evidence of their identity. IMP is', 'packed in identical boxes, with non-sequential kit numbers to ensure that unblinding does not', 'occur during shipment and handling of the drug.', 'Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will', 'be handled and administered by a qualified, unblinded HCP (trained site staff) at the site who', 'will not be involved in the management of trial subjects and who will not perform any of the', 'assessments.', 'If treatment allocation for a subject becomes known to the investigator or other trial staff', 'involved in the management of trial subjects, LEO must be notified immediately.', 'Should an issue arise with the IMP (e.g., damaged kit or syringe that has been assigned to a', 'subject prior to administration, or any other unexpected event with the kit or syringe [e.g., a', 'malfunction during IMP administration]), the unblinded HCP at the site will contact the', 'clinical research associate (CRA) to determine whether any specific actions are required.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 52 of 129', 'The trial site will maintain a written plan detailing which staff members are blinded/unblinded', 'and the process of IMP administration used to maintain the blind.', 'To support submission for marketing approval, an analysis of trial data up to and including', 'visit 19 (Week 32) will be performed and will require unblinding of data. To perform this', 'analysis, an Analysis Group consisting of a Medical Expert, a Statistician, a Statistical', 'Programmer and a Medical Writer will be unblinded to individual subject treatment allocation', 'following database lock for the 32-week data. All staff involved in the conduct of the trial will', 'remain blinded to treatment allocation for the entire duration of the trial. This principle will be', 'applied to all investigator staff and to staff employed by the sponsor except for those who are', 'directly involved in the execution of the analysis. See Section 12.3.11 for details regarding the', 'statistical aspects of the analysis of data up to Week 32.', '9.2.2 Emergency unblinding of individual subject treatment', 'While the safety of a subject always comes first, it is still important to carefully consider if', \"unblinding is necessary to ensure a subject's safety. An emergency unblinding request can be\", 'made by the investigators, other HCPs who are not members of the trial staff, or authorised', 'LEO personnel.', 'Provisions are in place for 24-hour emergency unblinding of individual subject treatment. If', \"emergency unblinding is required, the investigator can unblind a subject's treatment in the\", 'IWRS. For a requester who is not a member of the trial staff and who does not have access to', 'IWRS (e.g., a physician at an emergency room), a local contact number for the emergency', 'unblinding contract research organisation (CRO) is provided on the subject card (see', 'Appendix 3B) to be used if the investigator or delegated site staff cannot be reached. The', 'requester will provide the trial ID and subject ID to the emergency unblinding CRO who will', 'immediately reveal the individual treatment allocation.', 'The emergency unblinding CRO will clarify that the requester requires immediate unblinding', 'without further medical consultation. Should the requester wish to discuss whether unblinding', 'is necessary, the emergency unblinding CRO will provide the requester with the LEO 24/7', 'contact which will be diverted to the medical cover.', '9.3 Background treatment (emollients)', 'All subjects must use an emollient twice daily (or more, as needed) for at least 14 days before', 'randomisation; the background treatment should preferably be an additive free, basic bland', 'emollient. On lesional skin, emollients should only be applied at times where TCS is not', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}